Therefore, in addition to lowering total plasma Hcy, these patients may benefit from using AT1 receptor blockers rather than ACEIs, as our data showed that enalapril does not inhibit Hcy-induced AT1 receptor activation and HHcy-aggravated AAA formation, while telmisartan does. The gene discussed is AGTR1; the disease is triple-A syndrome.